Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Otsuka Holdings Co., Ltd. (4578.T)
Tokyo, TKY, JP
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.16% | -0.09% | +2.76% | +9.38% | +32.43% | +29.46% | +59.39% | +125.33% | +159.41% | +156.57% | +447.43% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 6 | 0 |
| Hold | 3 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+6.0% Q1'26: +8.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+8.1% Q1'26: +17.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+7.6% Q1'26: +13.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+16.7% Q1'26: +18.2% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+11.6% ★ Q1'26: +12.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-2.1% ★ Q1'26: -1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.43× ★ Q1'26: 0.34× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 11 EPS Ana. |
Dec 2027 12 Rev. Ana. 11 EPS Ana. |
Dec 2028 11 Rev. Ana. 11 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.45T
est: 1.41T (+2.5%)
|
1.20T
est: 1.21T (-1.1%)
|
1.24T
est: 1.24T (+0.2%)
|
1.29T
est: 1.29T (+0.0%)
|
1.40T
est: 1.40T (-0.3%)
|
1.42T
est: 1.43T (-0.2%)
|
1.50T
est: 1.48T (+1.0%)
|
1.74T
est: 1.70T (+2.4%)
|
2.02T
est: 2.18T (-7.4%)
|
2.33T
est: 2.32T (+0.3%)
|
2.47T
est: 2.43T (+1.7%)
|
2.58T
2.51T – 2.66T
+6.4% YoY
|
2.65T
2.48T – 2.75T
+2.6% YoY
|
2.77T
2.77T – 2.77T
+4.4% YoY
|
2.82T
2.69T – 2.91T
+1.8% YoY
|
2.79T
2.66T – 2.88T
-1.0% YoY
|
| EBITDA |
220.62B
est: 229.57B (-3.9%)
|
145.29B
est: 196.88B (-26.2%)
|
147.17B
est: 201.53B (-27.0%)
|
133.14B
est: 210.29B (-36.7%)
|
250.14B
est: 228.11B (+9.7%)
|
291.03B
est: 232.07B (+25.4%)
|
231.43B
est: 241.51B (-4.2%)
|
279.83B
est: 276.41B (+1.2%)
|
385.37B
est: 648.99B (-40.6%)
|
522.98B
est: 691.58B (-24.4%)
|
528.60B
est: 722.87B (-26.9%)
|
768.88B
748.02B – 790.51B
+6.4% YoY
|
789.19B
738.68B – 819.07B
+2.6% YoY
|
823.56B
823.43B – 823.70B
+4.4% YoY
|
838.47B
800.07B – 866.19B
+1.8% YoY
|
830.44B
792.40B – 857.89B
-1.0% YoY
|
| EBIT |
151.84B
est: 155.91B (-2.6%)
|
85.72B
est: 133.72B (-35.9%)
|
84.93B
est: 136.87B (-37.9%)
|
73.87B
est: 142.82B (-48.3%)
|
174.44B
est: 154.93B (+12.6%)
|
211.61B
est: 157.61B (+34.3%)
|
146.58B
est: 164.02B (-10.6%)
|
186.07B
est: 187.73B (-0.9%)
|
291.67B
est: 571.58B (-49.0%)
|
415.00B
est: 609.10B (-31.9%)
|
412.43B
est: 636.65B (-35.2%)
|
677.17B
658.80B – 696.23B
+6.4% YoY
|
695.06B
650.58B – 721.38B
+2.6% YoY
|
725.34B
725.22B – 725.45B
+4.4% YoY
|
738.46B
704.64B – 762.88B
+1.8% YoY
|
731.39B
697.89B – 755.57B
-1.0% YoY
|
| Net Income |
84.09B
est: 101.78B (-17.4%)
|
92.56B
est: 85.03B (+8.9%)
|
112.49B
est: 90.78B (+23.9%)
|
82.49B
est: 101.84B (-19.0%)
|
127.15B
est: 129.54B (-1.8%)
|
148.14B
est: 152.56B (-2.9%)
|
125.46B
est: 152.54B (-17.7%)
|
133.91B
est: 131.71B (+1.7%)
|
121.62B
est: 126.82B (-4.1%)
|
343.12B
est: 250.70B (+36.9%)
|
363.15B
est: 333.07B (+9.0%)
|
310.77B
276.80B – 357.04B
-6.7% YoY
|
329.95B
288.18B – 378.06B
+6.2% YoY
|
380.95B
298.18B – 500.64B
+15.5% YoY
|
418.68B
393.75B – 436.67B
+9.9% YoY
|
426.94B
401.52B – 445.29B
+2.0% YoY
|
| SGA |
597.35B
est: 574.88B (+3.9%)
|
535.85B
est: 493.03B (+8.7%)
|
558.68B
est: 504.68B (+10.7%)
|
564.37B
est: 526.60B (+7.2%)
|
557.61B
est: 571.24B (-2.4%)
|
562.43B
est: 581.15B (-3.2%)
|
622.33B
est: 604.78B (+2.9%)
|
724.13B
est: 692.19B (+4.6%)
|
807.36B
est: 893.86B (-9.7%)
|
958.35B
est: 952.52B (+0.6%)
|
1.00T
est: 995.62B (+0.9%)
|
1.06T
1.03T – 1.09T
+6.4% YoY
|
1.09T
1.02T – 1.13T
+2.6% YoY
|
1.13T
1.13T – 1.13T
+4.4% YoY
|
1.15T
1.10T – 1.19T
+1.8% YoY
|
1.14T
1.09T – 1.18T
-1.0% YoY
|
| EPS |
188.16
est: 188.00 (+0.1%)
|
170.82
est: 157.05 (+8.8%)
|
207.60
est: 167.67 (+23.8%)
|
152.24
est: 188.11 (-19.1%)
|
234.55
est: 239.26 (-2.0%)
|
273.16
est: 281.78 (-3.1%)
|
231.32
est: 281.74 (-17.9%)
|
246.81
est: 243.28 (+1.5%)
|
224.11
est: 233.67 (-4.1%)
|
633.76
est: 476.87 (+32.9%)
|
685.06
est: 633.56 (+8.1%)
|
590.28
522.16 – 673.54
-6.8% YoY
|
634.64
543.63 – 713.19
+7.5% YoY
|
729.55
562.49 – 944.43
+15.0% YoY
|
789.82
742.79 – 823.76
+8.3% YoY
|
805.40
757.45 – 840.01
+2.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Makoto Inoue | President, Chief Executive Officer & Representative Director | 233M | male |
| Yoshiro Matsuo | Executive Deputy President & Representative Director | 123M | male |
| Noriko Tojo | Executive Director | 110M | female |
| Shuichi Takagi | Executive Director | 110M | male |
| Masayuki Kobayashi | Executive Director | 110M | male |
| Yuko Makino | Chief Financial Officer & Executive Director | 65M | female |
| Manabu Kawata | Executive Vice President & Operating Officer of Business Development Department | — | — |
| Tomohiro Emura | Executive Vice President & Operating Officer of IR, Public Relations, and Sustainability Promotion | — | — |
| Keiso Yamasaki | Executive Vice President, Operating Officer & Director of Corporation Planning Dept., Bus. Insights and Analytics | — | — |
| Chiaki Sakurai | Senior EVice President, Operating Officer & Dir. of Nutraceutical Bus., Global Strat. and Planning Headquarters | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4578.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
